Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update
- PMID: 36000460
- DOI: 10.1177/12034754221116115
Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update
Abstract
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that is characterized by the formation of comedones, papules, nodules, abscesses and sinus tracts in the axillary, inframammary, groin, and gluteal areas. Up to 3.8% of the Canadian population has HS, though due to a lack of awareness of HS, many patients are initially misdiagnosed and do not receive adequate treatment early on in the disease course. Once a diagnosis of HS is made, developing an effective management plan can be a dilemma for many providers. There is significant variability in response to any given therapy within the HS patient population and many HS patients have other medical comorbidities which must be taken into consideration. The aim of this review is to provide a practical approach for all healthcare providers to diagnose and manage HS and its associated comorbidities. A sample electronic medical record template for HS management was developed by the Canadian Hidradenitis Suppurativa Foundation Executive Board and is intended for use in clinical settings. This will help to increase collaboration between primary healthcare providers, dermatologists, and other medical specialists and ultimately improve the quality of care that HS patients receive.
Keywords: guidelines; hidradenitis suppurativa; review.
Similar articles
-
Pediatric Hidradenitis Suppurativa: An Overview.Skin Therapy Lett. 2025 Jan;30(1):1-4. Skin Therapy Lett. 2025. PMID: 39814056 Review.
-
Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department.J Emerg Med. 2022 Nov;63(5):636-644. doi: 10.1016/j.jemermed.2022.08.001. Epub 2022 Oct 12. J Emerg Med. 2022. PMID: 36243614 Review.
-
Psychiatric comorbidities in patients with hidradenitis suppurativa.Dermatol Ther. 2020 Jul;33(4):e13541. doi: 10.1111/dth.13541. Epub 2020 May 22. Dermatol Ther. 2020. PMID: 32385861 Review.
-
Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa/Acne Inversa.Dermatology. 2017;233(2-3):113-119. doi: 10.1159/000477459. Epub 2017 Jul 7. Dermatology. 2017. PMID: 28683447 Review.
-
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110. Acta Dermatovenerol Croat. 2021. PMID: 34477078
Cited by
-
Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.Front Med (Lausanne). 2024 Jul 8;11:1403455. doi: 10.3389/fmed.2024.1403455. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39040895 Free PMC article. Review.
-
The Impact of Diet on Hidradenitis Suppurativa Severity: A Cross-Sectional Case-Control Study.Medicina (Kaunas). 2024 Dec 23;60(12):2107. doi: 10.3390/medicina60122107. Medicina (Kaunas). 2024. PMID: 39768986 Free PMC article.
-
Improving hidradenitis suppurativa management: consensus statements from physicians and patients' perspectives.Arch Dermatol Res. 2024 Aug 24;316(8):577. doi: 10.1007/s00403-024-03316-2. Arch Dermatol Res. 2024. PMID: 39180694 Free PMC article. Review.
-
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19. J Eur Acad Dermatol Venereol. 2025. PMID: 39699926 Free PMC article.
-
Australasian hidradenitis suppurativa management guidelines.Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22. Australas J Dermatol. 2025. PMID: 39578415 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical